Core Insights - AI-Media has launched an ADA Title II Compliance Initiative to assist state and local governments in meeting new federal accessibility requirements for digital content [1][4] - The U.S. Department of Justice finalized the ADA Title II Web and Mobile Accessibility Rule, mandating compliance with WCAG 2.1 Level AA, with deadlines starting April 24, 2026, for larger entities [2] - AI-Media's initiative includes a 10-Point ADA Title II Compliance Checklist and highlights its LEXI Text and LEXI AD technologies as essential tools for compliance [4][6] Compliance Initiative - The initiative aims to provide educational resources and practical tools to help government agencies prepare for upcoming compliance deadlines [3] - AI-Media will host a national webinar on January 20, 2026, to discuss accessibility requirements and how AI solutions can facilitate compliance [5] Technology Solutions - LEXI Text offers AI-powered captioning and transcription services to meet WCAG captioning and transcript requirements [11] - LEXI AD provides AI-driven audio description with advanced customization options, crucial for meeting WCAG 2.1 AA standards for prerecorded video [11]

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Core Insights - AIM ImmunoTech Inc. reported solid clinical and operational execution in Q3 2025, focusing on advancing Ampligen towards FDA approval for pancreatic cancer treatment [2] - Positive mid-year safety and efficacy data from the DURIPANC clinical trial combining Ampligen with AstraZeneca's Imfinzi were highlighted, with a year-end update expected [2] Financial Highlights - As of September 30, 2025, AIM reported cash, cash equivalents, and marketable investments of $2.4 million [8] - Research and development expenses for Q3 2025 were approximately $607,000, a decrease from $1.4 million in Q3 2024 [8] - General and administrative expenses were approximately $1.8 million for Q3 2025, down from $3.1 million in the same period of 2024 [8] - The net loss from operations for Q3 2025 was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for Q3 2024 [8] - The company expects a monthly burn rate of approximately $550,000 while maintaining operational efficiencies [8]

Financial Performance - Net loss for the three months ended September 30, 2025, was approximately $3,284,000, a decrease of 11% from $3,700,000 in the same period of 2024[221] - The company incurred a net loss of approximately $9,783,000 for the nine months ended September 30, 2025, a decrease of 14% from $11,353,000 in 2024[234] Revenue and Income - Revenues from the Ampligen® Cost Recovery Program decreased to $26,000 for the three months ended September 30, 2025, down from $35,000 in 2024, reflecting a decrease of $9,000[223] - Interest and other income increased significantly to approximately $3,052,000 for the three months ended September 30, 2025, compared to $718,000 in 2024, an increase of approximately $2,334,000[225] Expenses - Research and Development costs decreased to approximately $607,000 for the three months ended September 30, 2025, down from $1,437,000 in 2024, reflecting a decrease of approximately $830,000[228] - General and Administrative expenses decreased to approximately $1,798,000 for the three months ended September 30, 2025, from $3,079,000 in 2024, a reduction of approximately $1,281,000[229] Cash Flow - Cash used in operating activities for the nine months ended September 30, 2025, was approximately $8,971,000, a decrease of $1,962,000 from $10,933,000 in 2024[247] - Cash provided by financing activities increased to approximately $7,669,000 for the nine months ended September 30, 2025, compared to $5,407,000 in 2024, an increase of $2,262,000[249] - As of September 30, 2025, the company had approximately $2,409,000 in cash and cash equivalents, a decrease of approximately $1,568,000 from December 31, 2024[250] Stockholder Equity and Compliance - As of September 30, 2025, the company's stockholders' deficit was approximately ($6,077,000), necessitating an increase in stockholders' equity to at least $6,000,000 to regain compliance with exchange listing requirements[259] - The company is required to maintain Stockholders Equity of $6,000,000 to comply with NYSE American continued listing requirements[295] Securities and Financing Activities - The company filed a Universal Shelf Registration Statement to register the offering of up to $100,000,000 of various securities, which has not yet been declared effective[262] - An Equity Distribution Agreement with Maxim allows the company to issue and sell up to $3,000,000 of common stock, with a commission of 3.0% on gross proceeds from each sale[263][266] - The company has entered into a Purchase Agreement with Atlas Sciences, committing to purchase up to $15,000,000 of common stock, with the registration statement declared effective on May 1, 2024[272][273] - As of September 30, 2025, a total of 30,829 shares have been issued under the Purchase Agreement for approximately $398,000 after clearing costs[282] - On June 3, 2024, the company issued 56,410 shares of common stock and warrants to a single accredited investor, with warrants exercisable at $36.30 per share[283] - The company received approximately $1,260,000 in gross proceeds from the Transactions before deducting fees to the Placement Agent and other estimated offering expenses[290] - The company issued 46,530 shares of common stock at a purchase price of $28.00 per share in a registered direct offering[289] - The Class E and F warrants were issued at a combined public offering price of $4.00 per share, with gross proceeds of approximately $8,000,000 before deducting placement agent fees and offering expenses[293] - The exercise price for the Class C and Class D Warrants is set at $28.00, and they are not exercisable until December 3, 2024[291] - The Common Warrants have an allocated proceeds total of approximately $2,500,000, with no warrants exercised for the nine months ended September 30, 2025[288] - The Class E and F Warrants were classified as liabilities on the balance sheet as they may require the company to issue additional stock under certain circumstances[294] - The Placement Agent received a cash fee of 8% of the aggregate gross proceeds from the securities sold in the Transactions[287] - The registration statement for the resale of Common Warrant Shares was declared effective by the SEC on July 11, 2024[286] Other Financial Obligations - The company recognized losses from warrant issuances of $4,410,000 during the nine months ended September 30, 2025[234] - The company has an outstanding deposit of $240,000 as of September 30, 2025, which may be used to offset future clinical research expenditures[256] - The company entered into a Forbearance Agreement with a lender, resulting in an outstanding balance of $2,484,000 after applying a 1% fee[257] - The company has a lock-up agreement preventing executive officers and directors from selling securities for 90 days following the closing of the Transactions[285]

Core Insights - AIM ImmunoTech Inc. presented data from a Phase 2 clinical study on Ampligen for advanced recurrent ovarian cancer, showing promising results at the 40th Annual SITC Meeting [1][2] Study Results - The study involved 27 platinum-sensitive patients, with 24 evaluable for response; 5 achieved complete response and 7 had partial response, resulting in an Objective Response Rate (ORR) of 50% [2] - This ORR is significantly higher compared to previous studies, such as Keynote-100, which reported ORRs of 7.4% and 9.9% for pembrolizumab alone [2] Mechanism and Potential - AIM believes that Ampligen can act synergistically with checkpoint inhibitors, potentially benefiting patients who do not respond to these therapies alone [3] - The study's findings suggest that Ampligen may enhance traditional cancer treatments, improving immune responses and prolonging remission for patients with limited options [4] Intellectual Property - AIM holds several patents related to the use of Ampligen in combination with checkpoint inhibitors, with expiration dates ranging from 2039 to 2040 in various jurisdictions [5] Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen as its lead investigational drug [7]

Core Insights - AIM ImmunoTech Inc. announced that data from its Phase 2 clinical study on cisplatin-resistant advanced recurrent ovarian cancer using Ampligen (rintatolimod) was accepted for presentation at the 40th Annual SITC Meeting [1] - The study focuses on a combination locoregional chemoimmunotherapy approach and its correlation with clinical outcomes [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [2]

Core Insights - AIM ImmunoTech Inc. has been granted a European patent for its proprietary dsRNA compositions aimed at treating Long COVID, specifically covering Ampligen (rintatolimod) [1] - The company is focused on advancing its pancreatic cancer clinical program while the new patent enhances its intellectual property portfolio and validates Ampligen's potential as a broad-spectrum immunotherapy [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The lead product, Ampligen, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist, demonstrating broad-spectrum activity in clinical trials [4] Clinical Research and Development - Ampligen has shown a broad-spectrum, early-onset antiviral effect by stimulating a strong innate immune response, with data indicating significant decreases in viral replication in SARS-CoV-1 studies [3] - A Phase 2 study (AMP-518) has reported positive topline results, suggesting that Ampligen is generally well tolerated and may reduce fatigue in patients with Long COVID [3]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories - **User Experience** - Enabling Javascript and cookies is crucial for seamless browsing [1] - Ad-blockers can hinder access to certain content [1]

Core Points - AIM ImmunoTech Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, NY, which focuses on industry trends and advancements [1] - Management will be available for in-person one-on-one meetings with registered investors during the conference [2] - AIM ImmunoTech is an immuno-pharma company developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen, currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca [4] Company Information - AIM ImmunoTech Inc. specializes in research and development of therapeutics targeting multiple diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist [4] - AIM ImmunoTech is focused on broad-spectrum activity in clinical trials, particularly in combination therapies for cancer treatment [4] Event Information - The Maxim Growth Summit is organized by Maxim Group LLC, a full-service investment banking and wealth management firm based in New York [3] - The summit will feature industry leaders and innovators discussing the latest trends across various sectors [1] - For more details on the summit agenda and AIM's presentation, interested parties can visit the respective websites [2]

Core Viewpoint - AIM ImmunoTech Inc. has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors who adjust their valuations based on these estimates [4][6]. - For AIM ImmunoTech, the recent upgrade reflects an improvement in the company's business fundamentals, suggesting that investor sentiment may lead to increased stock prices [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, AIM ImmunoTech is projected to earn -$6.79 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 78.1% over the past three months, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, positioning AIM ImmunoTech favorably for potential market-beating returns [9][10].